Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

112.09 +2.45 (+2.23%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
61 62 Next >
$100 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Can These 3 Healthcare Dividend Stocks Deliver Income Growth?
Healthcare-sector dividend payers Pfizer, Medtronic, and Gilead all boosted shareholder payouts and trade at low multiples relative to potential price gains. 
Via MarketBeat
Kite’s Car T-cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
Wave of FDA Fast Track Designations Highlight Biotech Momentum Carrying into 2023
FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 13, 2023 – USA News Group – Sufferers of many different ailments saw reason to grow their hope in 2022 when the US Food... 
Via FinancialNewsMedia
$1000 Invested In This Stock 20 Years Ago Would Be Worth $9,000 Today
Via Benzinga
Time For Gilead Sciences-Heavy ETFs?
Gilead Sciences has underperformed the broader market this year by a hefty margin. 
Via Talk Markets
Gilead's Breast Cancer Drug Shows Promise When Combined With Merck's Treatment
Gilead Sciences Inc (NASDAQ: GILD) revealed early data from its open-label, Phase 2 EVOKE-02 study evaluating Trodelvy. 
Via Benzinga
Gilead’s Phase 2 EVOKE-02 Study of Trodelvy® (sacituzumab govitecan-hziy) in Combination With KEYTRUDA® (pembrolizumab) Demonstrates Promising Clinical Activity in First-Line Metastatic Non-Small Cell Lung Cancer
From Gilead Sciences, Inc.
Via Business Wire
What You Need to Know About Hepatitis C This Recovery Month
(BPT) - Hepatitis C (HCV) is often referred to as the 'silent disease' due to silent symptoms that may not appear until years after exposure. In fact, of the more than 2 million Americans who are... 
Via Brandpoint
How To Earn $500 A Month From Gilead Sciences Stock
Shares of Gilead Sciences, Inc (NASDAQ: GILD) are trading higher during Friday’s trading session, bolstered by the Bank of America Securities bullish outlook on the stock. 
Via Benzinga
Where Gilead Sciences Stands With Analysts
Via Benzinga
(GILD) - Analyzing Gilead Sciences's Short Interest
Via Benzinga
Infectious Disease Player Vir Biotech Has Limited Near Term Upside, Analyst Downgrades
BofA Securities has downgraded Vir Biotechnology Inc (NASDAQ: VIR) to Neutral from Buy with a price target of $14,  
Via Benzinga
The Unexpected Reason Gilead Just Notched Its Biggest Single-Day Move In A Month
Gilead shares are on the rise amid an unexpected boon for its HIV treatment business. 
Via Investor's Business Daily
Gilead Sciences Shares Trade Higher After Bullish Analyst Upgrades Stock
Shares of Gilead Sciences, Inc. (NASDAQ: GILD) are trading higher into Friday’s trading session after Bank of America Securities upgraded the stock, highlighting an underappreciated growth potential in... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 8, 2023
Via Benzinga
Adobe To Rally Over 12%? Here Are 10 Other Analyst Forecasts For Friday
B of A Securities cut the price target for DigitalOcean Holdings, Inc. (NYSE: DOCN) from $47 to $25. B of A Securities analyst Wamsi Mohan downgraded the stock from Buy to Underperform. DigitalOcean... 
Via Benzinga
Gilead Prices $2 Billion of Senior Unsecured Notes
From Gilead Sciences, Inc.
Via Business Wire
3 No-Brainer Dividend Stocks to Buy in September
Income investors should really like these biopharma stocks with juicy dividends. 
Via The Motley Fool
Nearing Retirement? These Stocks Will Pay You For Life
These companies are passive income machines. 
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
Via Benzinga
GILD Stock Alert: FDA Approves Gilead Sciences’ Veklury Covid-19 Treatment
Gilead Sciences (GILD) stock is on the move Thursday following additional FDA approval for its Veklury Covid-19 treatment. 
Via InvestorPlace
FDA Approves Veklury® (Remdesivir) to Treat COVID-19 in People With Mild to Severe Hepatic Impairment With no Dose Adjustment
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences to Present at Upcoming Investor Conferences
From Gilead Sciences, Inc.
Via Business Wire
Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update
Earlier today, Roche Holdings AG (OTC: RHHBY) announced that it had been made aware of inadvertent disclosure of the second interim analysis of Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab plus... 
Via Benzinga
How Roche's Accidental Cancer Update Lifted Iteos And Arcus More Than 30%
Roche provided an update from its study in lung cancer using an anti-TIGIT drug. 
Via Investor's Business Daily
San Francisco Business Times Names Landis Communications Inc. (Landis) the Top 2022 Bay Area Corporate Philanthropist as a Percentage Of Profits
--News Direct-- 
Via News Direct
Topics LGBTQ
Large Cap Biopharmaceuticals Performance 2023 YTD: Mixed Results But Lilly Is A Big Winner
Biotech stocks are in a bear market since the IBB hit $177.37 in 2021 and is down 7.84% over five years. 
Via Talk Markets
FDA Pauses Gilead's Investigational Magrolimab Study In Blood Cancer Patients
FDA has placed a partial clinical hold on Gilead Sciences Inc (NASDAQ: GILD) initiation of new patients in U.S. 
Via Benzinga
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
61 62 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback